Two unprecedented 2-(2-phenethyl)chromone derivatives with anti-Helicobacter pylori and anti-inflammatory activities from agarwood of Aquilaria crassna

IF 1.4 4区生物学 Q4 CHEMISTRY, MEDICINAL

Phytochemistry Letters Pub Date : 2025-08-30 DOI:10.1016/j.phytol.2025.103039

Xiao-Hong Li , Hao Wang , Wen-Li Mei , Wen-Hua Dong , Jun Zeng , Sheng-Zhuo Huang , Hui-Qin Chen , Yan-Mei Wei , Fei Wu , Zhi-Yong Guo , Hao-Fu Dai

引用次数: 0

Abstract

Two unprecedented 2-(2-phenethyl)chromone derivatives, 4′-demethoxy-aquisinenin I (1) and 6"-methoxy-crassna B (2)，together with a known 2-(2-phenylethyl)chromone dimer (3), were isolated from the ethanol extract of agarwood of Aquilaria crassna. Their structures were constructed through comprehensive spectroscopic analysis, including 1D and 2D NMR, HRESIMS. All compounds were screened for their anti-Helicobacter pylori activity and ability to inhibit nitric oxide production in lipopolysaccharide (LPS)-stimulated RAW264.7 cells. Compound 1 exhibited anti-Helicobacter pylori effect with a MIC value of 40 µM, and anti-inflammatory activity with an IC₅₀ value of 14.10 ± 1.04 μM.

Abstract Image

查看原文本刊更多论文

两种前所未有的具有抗幽门螺杆菌和抗炎活性的沉香2-（2-苯基）色素衍生物

从沉香木乙醇提取物中分离得到2-（2-苯乙基）色素衍生物4′-去甲氧基-aquisinenin I(1)和6′-甲氧基-crassna B(2)，以及一种已知的2-（2-苯乙基）色素二聚体(3)。通过全面的光谱分析，包括1D和2D NMR， HRESIMS，构建了它们的结构。筛选所有化合物的抗幽门螺杆菌活性和抑制脂多糖（LPS）刺激的RAW264.7细胞一氧化氮生成的能力。化合物1具有抗幽门螺杆菌作用，MIC值为40 µM， IC50值为14.10 ± 1.04 μM。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Phytochemistry Letters 生物-生化与分子生物学

CiteScore

3.00

自引率

11.80%

发文量

190

审稿时长

34 days

期刊介绍： Phytochemistry Letters invites rapid communications on all aspects of natural product research including: • Structural elucidation of natural products • Analytical evaluation of herbal medicines • Clinical efficacy, safety and pharmacovigilance of herbal medicines • Natural product biosynthesis • Natural product synthesis and chemical modification • Natural product metabolism • Chemical ecology • Biotechnology • Bioassay-guided isolation • Pharmacognosy • Pharmacology of natural products • Metabolomics • Ethnobotany and traditional usage • Genetics of natural products Manuscripts that detail the isolation of just one new compound are not substantial enough to be sent out of review and are out of scope. Furthermore, where pharmacology has been performed on one new compound to increase the amount of novel data, the pharmacology must be substantial and/or related to the medicinal use of the producing organism.